Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
T-Rex 2X Inverse MSTR Daily Target ETF
MSTZ
5
Direxion Daily S&P 500 Bear 3X Shares ETF
SPXS
US Stock MarketDetailed Quotes
RLYB Rallybio
- 0.3028
- -0.0005-0.16%
Trading Apr 28 10:10 ET
12.60MMarket Cap-0.23P/E (TTM)
0.3031High0.2970Low15.38KVolume0.2970Open0.3033Pre Close4.60KTurnover0.08%Turnover RatioLossP/E (Static)41.61MShares2.000052wk High0.20P/B5.96MFloat Cap0.220152wk Low--Dividend TTM19.69MShs Float25.7800Historical High--Div YieldTTM2.01%Amplitude0.2201Historical Low0.2990Avg Price1Lot Size
Market Insights
Discussing
Trade war escalates: What’s next for Chinese stocks?
🎙️Discussion 1. China-EU EV negotiations kick off recently. How do you think the negotiations will impact the performance of related stocks
Moo Earnings
Feb 17 19:21
Alibaba Q4 FY2024 Earnings Preview: Predict & Win Big! 🚀
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
Unlock Now
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Unlock Now
Discussing
Trump 2.0 Era: How will global markets evolve?
🎙️Discussion: 1. How will tariff policies affect the movement of key assets such as U.S. stocks, gold, and Bitcoin? 2. Given this context,
Moo Live
Jan 23 16:54
MicroStrategy Q4 2024 earnings conference call
Rallybio Stock Forum
Major Pipeline Shift: Rallybio Abandons FNAIT Drug to Target Lucrative $6B Disease Market
Rallybio Corp: Rlyb212 Phase 2 Pk Results Did Not Achieve Target Concentrations! Rallybio Corp - to Initiate Rlyb116 Pk/Pd Study in 2Q 2025
Rallybio Announces Initiation of Dosing in Rlyb212 Phase 2 Clinical Trial
Rallybio Announces Promising RLYB212 and RLYB332 Preclinical Data at the 66th American Society of Hematology Annual Meeting
Tuesday, 10th December at 8:00 am
Rallybio Corporation (NASDAQ: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced the presentation of two posters highlighting promising preclinical data for pipeline candidates RLYB212 and RLYB332 at ...
Rallybio to Initiate RLYB116 Confirmatory Clinical PK/PD Study in Second Quarter 2025
Monday, 2nd December at 8:00 am
-- New Biomarker Characterization Analyses Indicate RLYB116 Produced Complete and Sustained Complement Inhibition in Previous Phase 1 MAD Study –
-- Manufacturing Process Enhancements Expected to Further Improve RLYB116 Tolerability --
3 MINUTES AGO, 8:00 AM EST
VIA BUSINESSWIRE
— Dosing Regimen to be Evaluated in Recently Initiated RLYB212 Phase 2 Clinical Trial —
Rallybio Announces Publication of Target-Mediated Drug Disposition Modeling and Simulations Informing the RLYB212 Dosing Regimen in Pregnant Women
Rallybio announced the publication of a manuscript detailing target-mediated drug disposition (TMDD) modeling used to determine RLYB212 dosing for pregnant women.
The model incorporates pregnancy-related physiological changes and will be evaluated in their recently initiated Phase 2 clinical trial. RLYB212 is being developed ...
Rallybio Announces Initiation of Phase 2 Clinical Trial of RLYB212
— Screening is Now Underway to Identify Pregnant Women at Higher Risk for HPA-1a Alloimmunization and FNAIT —
Rallybio Corporation (NASDAQ:RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced the initiation of its Phase 2 clinical trial investigating RLYB212 in pregnant women at higher risk ...
Rallybio Announces Approval of Clinical Trial Applications for Phase 2 Trial of Rlyb212 in Pregnant Women at Higher Risk of Alloimmunization and Fnait
Rallybio to Present Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse Populations at the American Society of Human Genetics 2024 Annual Meeting
Rallybio (Nasdaq: RLYB) will present full data from an epidemiological analysis at the American Society of Human Genetics (ASHG) 2024 Annual Meetingin Denver, CO. The analysis quantifies the proportion of women across diverse populations at higher risk of a fetal and neonatal alloi...
No comment yet